| Index | — | P/E | — | EPS (ttm) | -1.86 | Insider Own | 46.70% | Shs Outstand | 169.22M | Perf Week | 6.91% |
| Market Cap | 1.91B | Forward P/E | — | EPS next Y | -2.55 | Insider Trans | -0.00% | Shs Float | 129.82M | Perf Month | 0.09% |
| Enterprise Value | 1.47B | PEG | — | EPS next Q | -0.74 | Short Float | 12.51% | Perf Quarter | 26.97% | ||
| Income | -252.00M | P/S | 6.31 | EPS this Y | — | Short Ratio | 8.37 | Perf Half Y | 13.00% | ||
| Sales | 303.00M | P/B | 1.95 | EPS next Y | — | ROA | -20.72% | Short Interest | 16.24M | Perf YTD | 87.40% |
| Book/sh | 5.80 | P/C | 3.61 | EPS next 5Y | — | ROE | -29.99% | 52W High | 12.19 -7.30% | Perf Year | 91.20% |
| Cash/sh | 3.13 | P/FCF | — | EPS past 3/5Y | — | ROIC | -24.75% | 52W Low | 4.82 134.44% | Perf 3Y | 35.98% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -65.05% -1.91% | Gross Margin | 96.20% | Volatility | 5.99% 5.97% | Perf 5Y | -71.90% |
| Dividend TTM | — | EV/Sales | 4.84 | EPS Y/Y TTM | — | Oper. Margin | -92.16% | ATR (14) | 0.63 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 6.04 | Sales Y/Y TTM | 1583.33% | Profit Margin | -83.00% | RSI (14) | 53.83 | Recom | 2.17 |
| Dividend Gr. 3/5Y | — | Current Ratio | 6.04 | EPS Q/Q | 158.75% | SMA20 | 2.46% | Beta | 1.69 | Target Price | 23.50 |
| Payout | 0.00% | Debt/Eq | 0.09 | Sales Q/Q | 23800.00% | SMA50 | 3.25% | Rel Volume | 0.66 | Prev Close | 11.75 |
| Employees | 367 | LT Debt/Eq | 0.09 | Earnings | Nov 04 | SMA200 | 18.69% | Avg Volume | 1.93M | Price | 11.30 |
| IPO Date | Oct 11, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 41.31% 75.85% | Net Debt/EBITDA | — | Volume | 1,267,213 | Change | -3.83% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-07-26 | Reiterated | HC Wainwright & Co. | Buy | $20 → $22 |
| Aug-06-26 | Reiterated | Morgan Stanley | Overweight | $27 → $25 |
| Jun-11-26 | Reiterated | Morgan Stanley | Overweight | $23 → $27 |
| May-08-26 | Reiterated | Morgan Stanley | Overweight | $24 → $23 |
| Mar-04-26 | Reiterated | HC Wainwright & Co. | Buy | $15 → $20 |
| Feb-26-26 | Reiterated | Leerink Partners | Outperform | $20 |
| Feb-24-26 | Reiterated | Raymond James | $12 → $19 | |
| Feb-24-26 | Reiterated | Morgan Stanley | Overweight | $20 → $24 |
| Feb-24-26 | Reiterated | Needham | Buy | $35 → $18 |
| Feb-24-26 | Reiterated | Evercore ISI Group | Outperform | $18 |
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 303 | 69 | 74 | 86 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 12 | 12 | 15 | 22 | — | — | — | — | — | |
| Gross Profit | 291 | 57 | 59 | 64 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 99 | 92 | 119 | 174 | — | — | — | — | — | |
| Research and Development | 472 | 433 | 463 | 551 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -279 | -468 | -523 | -661 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 29 | 30 | 0 | 33 | — | — | — | — | — | |
| Net Income Before Taxes | -252 | -438 | -523 | -628 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | -1 | -13 | — | — | — | — | — | |
| Consolidated Net Income | -252 | -438 | -522 | -615 | — | — | — | — | — | |
| Net Income From Continuing Operations | -252 | -438 | -522 | -615 | — | — | — | — | — | |
| Net Income | -252 | -438 | -522 | -615 | — | — | — | — | — | |
| EPS (Recurring) | -1.85 | -3.16 | -3.83 | -4.59 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.85 | -3.16 | -3.83 | -4.59 | — | — | — | — | — | |
| EPS (Diluted) | -1.86 | -3.16 | -3.83 | -4.59 | — | — | — | — | — | |
| EBITDA | -268 | -456 | -509 | -642 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.27 | 12.15 | 13.49 | 15.67 | — | — | — | — | — | |
| Gross Margin | 96.04 | 82.61 | 79.73 | 74.42 | — | — | — | — | — | |
| Operating Margin | -92.08 | -678.26 | -706.76 | -768.60 | — | — | — | — | — | |
| Net Margin | -83.17 | -634.78 | -705.41 | -715.12 | — | — | — | — | — | |
| Shares Outstanding | 168 | 139 | 136 | 134 | — | — | — | — | — | |
| Market Capitalization | 1,898 | 838 | 998 | 1,348 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Sabatini Brent | SVP, Chief Accounting Officer | Jun 01 '26 | Sale | 9.45 | 379 | 3,582 | 61,902 | Jun 02 |
| Napolitano Janet | Director | Jun 01 '26 | Sale | 9.45 | 3,200 | 30,240 | 21,216 | Jun 02 |
| SATO VICKI L | Director | May 01 '26 | Sale | 10.05 | 22,000 | 221,025 | 1,078,391 | May 04 |
| De Backer Marianne | President and CEO | Apr 06 '26 | Sale | 9.16 | 72,559 | 664,350 | 948,145 | Apr 07 |
| SATO VICKI L | Director | Apr 01 '26 | Sale | 9.07 | 22,000 | 199,617 | 1,100,391 | Apr 02 |
| Sabatini Brent | SVP, Chief Accounting Officer | Mar 23 '26 | Sale | 9.12 | 7,711 | 70,324 | 61,902 | Mar 24 |
| SATO VICKI L | Director | Mar 02 '26 | Sale | 9.51 | 22,000 | 209,181 | 1,122,391 | Mar 03 |
| de Verneuil Vanina | EVP, General Counsel, Corp Sec | Feb 25 '26 | Sale | 9.82 | 13,700 | 134,534 | 112,982 | Feb 26 |
| Eisner Mark | EVP and Chief Medical Officer | Feb 25 '26 | Sale | 9.82 | 1,889 | 18,550 | 154,024 | Feb 26 |
| O'Byrne Jason | EVP & Chief Financial Officer | Feb 24 '26 | Sale | 9.53 | 1,634 | 15,576 | 162,615 | Feb 26 |
| SATO VICKI L | Director | Feb 24 '26 | Option Exercise | 1.49 | 42,377 | 62,930 | 1,186,768 | Feb 26 |
| SATO VICKI L | Director | Feb 24 '26 | Sale | 9.75 | 42,377 | 413,366 | 1,144,391 | Feb 26 |
| Sabatini Brent | SVP, Chief Accounting Officer | Feb 24 '26 | Sale | 9.53 | 1,430 | 13,632 | 69,613 | Feb 26 |
| Eisner Mark | EVP and Chief Medical Officer | Feb 24 '26 | Sale | 9.53 | 1,616 | 15,405 | 155,913 | Feb 26 |
| de Verneuil Vanina | EVP, General Counsel, Corp Sec | Feb 24 '26 | Sale | 9.53 | 3,117 | 29,713 | 126,682 | Feb 26 |